NasVax: Closing Share Purchase Agreement of Protea Vaccine Technologies
Protea has become a fully owned subsidiary of NasVax
14-Jul-2009
- Israel
In June 2009, Protea announced that it signed a Research and License Option Agreement with GlaxoSmithKline to a set of Protea’s conserved pneumococcal proteins for the development and commercialization of a universal protein-based Streptococcus pneumoniae vaccine.
Protea is developing an next-generation vaccine against diseases caused by Streptococcus pneumoniae, based on widely conserved pneumococcal proteins.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.